NO951861L - ECK-reseptorligander - Google Patents

ECK-reseptorligander

Info

Publication number
NO951861L
NO951861L NO951861A NO951861A NO951861L NO 951861 L NO951861 L NO 951861L NO 951861 A NO951861 A NO 951861A NO 951861 A NO951861 A NO 951861A NO 951861 L NO951861 L NO 951861L
Authority
NO
Norway
Prior art keywords
eck receptor
eck
receptor
receptor ligands
ligands
Prior art date
Application number
NO951861A
Other languages
English (en)
Norwegian (no)
Other versions
NO951861D0 (no
Inventor
Timothy D Bartley
William J Boyle
Gary M Fox
Andrew A Welcher
Vann P Parker
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of NO951861D0 publication Critical patent/NO951861D0/no
Publication of NO951861L publication Critical patent/NO951861L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
NO951861A 1992-11-13 1995-05-11 ECK-reseptorligander NO951861L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97770892A 1992-11-13 1992-11-13
US14561693A 1993-11-09 1993-11-09
PCT/US1993/010879 WO1994011020A1 (fr) 1992-11-13 1993-11-12 LIGANDS DU RECEPTEUR $i(ECK)

Publications (2)

Publication Number Publication Date
NO951861D0 NO951861D0 (no) 1995-05-11
NO951861L true NO951861L (no) 1995-07-11

Family

ID=26843152

Family Applications (1)

Application Number Title Priority Date Filing Date
NO951861A NO951861L (no) 1992-11-13 1995-05-11 ECK-reseptorligander

Country Status (14)

Country Link
US (2) US5650504A (fr)
EP (1) EP0597503B1 (fr)
JP (1) JPH08505765A (fr)
CN (1) CN1094446A (fr)
AT (1) ATE172246T1 (fr)
AU (1) AU685765B2 (fr)
CA (1) CA2149333C (fr)
DE (1) DE69321555T2 (fr)
DK (1) DK0597503T3 (fr)
ES (1) ES2121915T3 (fr)
FI (1) FI952328A7 (fr)
IL (1) IL107599A0 (fr)
NO (1) NO951861L (fr)
WO (1) WO1994011020A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06504667A (ja) * 1990-10-16 1994-06-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 炎症性反応生起に関連するサイトカイン−誘起マーカー
WO1994011384A1 (fr) * 1992-11-13 1994-05-26 Immunex Corporation Nouvelle cytokine appelee ligand d'elk
US5824303A (en) * 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US5747033A (en) * 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
ATE232901T1 (de) * 1994-04-04 2003-03-15 Regeneron Pharma Biologisch aktive ligande der eph familie
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
EP0787148B1 (fr) * 1994-10-27 2004-04-07 Genentech, Inc. Facteur neurotrophique al-1, un ligand pour le recepteur tyrosine kinase apparente a eph
US5759775A (en) * 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
US6057124A (en) * 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
US6100346A (en) * 1995-03-06 2000-08-08 Ethicon, Inc. Copolymers of polyoxaamides
US6610296B2 (en) 1995-10-26 2003-08-26 Genentech, Inc. Methods of enhancing cognitive function using an AL-1 neurotrophic factor immunoadhesin
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
IL143558A0 (en) 1998-12-23 2002-04-21 Regeneron Pharma Method of enhancing the biological activity of ligands
US6248725B1 (en) 1999-02-23 2001-06-19 Amgen, Inc. Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
EP1873244A3 (fr) * 1999-06-02 2008-04-02 Genentech, Inc. Procédés et compositions d'inhibition de la croissance de cellules néoplasiques
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
US20020192711A1 (en) * 2001-04-20 2002-12-19 Nestor John J. Methods for identifying ligands of G-Protein-Coupled receptors
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
ATE525398T1 (de) * 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
JP4585968B2 (ja) * 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
EP1606305A4 (fr) 2003-03-12 2009-06-24 Vasgene Therapeutics Inc Composes d'acide nucleique pouvant inhiber l'angiogenese et la croissance tumorale
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
EP1618184A4 (fr) * 2003-04-11 2006-06-21 Medimmune Inc Epha2, troubles cellulaires hypoproliferatifs, et reconstitution epitheliale et endotheliale
WO2004091375A2 (fr) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 et troubles cellulaires hyperproliferatifs
CA2525929A1 (fr) * 2003-05-13 2004-11-25 Chiron Corporation Methodes de modulation de metastase et d'evenements lies au squelette resultant de metastases
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
DK1730196T3 (da) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
CA2581423A1 (fr) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Composes de polypeptides pour l'inhibition de l'angiogenese et de croissance tumorale
JP2008528614A (ja) 2005-01-27 2008-07-31 ザ・バーンハム・インスティテュート ＥｐｈＢ受容体結合ペプチド
CA2696164C (fr) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Traitement contre le cancer utilisant des anticorps humanises qui se lient a ephb4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001052A (nl) * 1990-05-02 1991-12-02 Tno Werkwijze voor het bepalen van een specifiek ligand in een vloeibaar monster met behulp van een evanescent veld, alsook een daarvoor geschikt onderdeel van de benodigde meetinrichting.
JPH06504667A (ja) * 1990-10-16 1994-06-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 炎症性反応生起に関連するサイトカイン−誘起マーカー

Also Published As

Publication number Publication date
DK0597503T3 (da) 1999-06-23
DE69321555D1 (de) 1998-11-19
US5650504A (en) 1997-07-22
NO951861D0 (no) 1995-05-11
AU685765B2 (en) 1998-01-29
FI952328L (fi) 1995-07-10
FI952328A0 (fi) 1995-05-12
FI952328A7 (fi) 1995-07-10
ATE172246T1 (de) 1998-10-15
US5716934A (en) 1998-02-10
WO1994011020A1 (fr) 1994-05-26
IL107599A0 (en) 1994-02-27
EP0597503A3 (fr) 1995-05-24
ES2121915T3 (es) 1998-12-16
DE69321555T2 (de) 1999-06-24
AU5599794A (en) 1994-06-08
EP0597503A2 (fr) 1994-05-18
CN1094446A (zh) 1994-11-02
JPH08505765A (ja) 1996-06-25
CA2149333A1 (fr) 1994-05-26
EP0597503B1 (fr) 1998-10-14
CA2149333C (fr) 2002-01-22

Similar Documents

Publication Publication Date Title
NO951861L (no) ECK-reseptorligander
WO1996036713A3 (fr) Ligands pour le recepteur eck
DK446386A (da) Proteinhydrolysater, fremgangsmaader til fremstilling deraf og laegemidler, der indeholder disse hydrolysater
DK214090D0 (da) 5-aminosulfonylalkyl-indolderivater, fremgangsmaade og mellemprodukt til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK164868C (da) Imidazooe4,5-baaquinolin-2-on-derivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK362787A (da) Benzensulfonamido-indanylforbindelser, laegemidler indeholdende disse forbindelser og fremgangsmaade til deres fremstilling
NO165966C (no) Fremgangsmaate for utvinning av chitin fra materialer hvorchitin opptrer sammen med, eller i tilknytning til, proteinsubstanser.
EP0194578A3 (en) Proteins immobilised on polyamides or cellulose hydrate and the use thereof for the preparation of biocatalysts, test strips or chromatography materials
NO962084L (no) DNA sekvens som koder for en BMP reseptor
FI895921A7 (fi) Entsyymireaktioita estävät aminohappojohdannaiset, menetelmä niiden valmistamiseksi, niitä sisältävät aineet ja niiden käyttö
DK66086D0 (da) Dihydropyridiner, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
ATE191568T1 (de) Spezifische bindungssubstanzen für antikörper und deren verwendung für immunoassays oder vakzine
DK457787A (da) Sulfonamidoethylforbindelser, laegemidler indeholdende disse forbindelser og fremgangsmaade til deres fremstilling
DK92789D0 (da) Polypeptidderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DK494088D0 (da) 4-oxo-3-quinolincarboxylsyrer, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DK105886A (da) Monoklone anti-alfa-amylaseantistoffer, fremgangsmaade til fremstilling heraf samt laegemidler indeholdende disse antistoffer
DK165885D0 (da) Peptider, fremgangsmaade til fremstilling deraf, samt farmaceutiske praeparater, indeholdende disse peptider
DK191086D0 (da) Benzisoselenazolonylderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
NO161684C (no) Endoproteinase-lyste f or utvinning av enzymet, samt anvendelse av enzymet til sekvensbestemmelse av proteiner og peptider.
DK2488A (da) Dopamin-beta-hydroxylaseinhibitorer, fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende disse
DK65986D0 (da) Dihydropyridiner, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse
DK164453C (da) Dibenzooeb,daathiopyran-6-carboxylsyreforbindelser, fremgangsmaade til fremstilling heraf og farmaceutiske praeparater indeholdende disse forbindelser
DK352586A (da) 11-methylen-aestr-15-ener, fremgangsmaader til deres fremstilling og farmaceutiske praeparater indeholdende disse aestrener
NO813974L (no) Bis-aminometyl-antrakinon-derivater, fremgangsmaate til deres fremstilling, midler inneholdende disse og deres anvendelse
DK623089A (da) Trombolytiske proteiner, fremgangsmaade til fremstilling deraf og praeparater indeholdende disse forbindelser

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application